Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer

Cancer Treat Rep. 1978 Apr;62(4):505-10.


Seventy-six patients with stage III bronchogenic carcinoma were treated with monthly adriamycin, cyclophosphamide, cis-dichlorodiammineplatinum(II), and vincristine. In addition, they were randomized to receive either no immunotherapy, the methanol extracted residue of bacillus Calmette-Guérin (MER), or Corynebacterium parvum (C. parvum). Age, histology, extent of disease, prior therapy, and performance status were comparable in the three treatment groups. Twelve patients (16%) died having received only one treatment cycle. Sixty-four of the 76 patients received two or more treatments and were evaluable for response. There were no patients with complete responses, 14 patients (18%) with partial responses, 28 patients (37%) with no change, and 22 patients (29%) with progressive disease. Survival among patients receiving C. parvum is significantly longer (P less than 0.05) than that of patients receiving either MER or no immunotherapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • BCG Vaccine / therapeutic use*
  • Bacterial Vaccines / therapeutic use*
  • Carcinoma, Bronchogenic / drug therapy
  • Carcinoma, Bronchogenic / therapy*
  • Cisplatin / therapeutic use
  • Clinical Trials as Topic
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Drug Therapy, Combination / adverse effects
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Propionibacterium acnes / immunology*
  • Time Factors
  • Vincristine / therapeutic use


  • BCG Vaccine
  • Bacterial Vaccines
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin